MORGAN STANLEY PLC/CALL/AMGEN/460/0.1/16.01.26 | Market Closed - Bid/Ask 09:14:04 2024-05-20 EDT | After market 14:08:42 | |||
| 0.97 EUR | -4.90% |
|
1.055 | +8.76% |
| Current month | +59.38% | ||
| 1 month | +54.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 0.97 | -4.90% |
| 24-05-17 | 1.02 | -4.67% |
| 24-05-16 | 1.07 | -3.60% |
| 24-05-15 | 1.11 | +11.00% |
| 24-05-14 | 1 | +1.01% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 09:14 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6QPC |
| ISIN | DE000ME6QPC6 |
| Date issued | 2024-01-10 |
| Strike | 460 $ |
| Maturity | 2026-01-16 (606 Days) |
| Parity | 10 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.26 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | 0.07 € |
| Spread % | 6.42% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.5
USD
Average target price
316.1
USD
Spread / Average Target
+1.15%
- Stock Market
- Warrants
- Warrant